Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy

The primary objectives of the study were to evaluate the efficacy and safety of tofacitinib and baricitinib up to 24 months of follow-up in patients with rheumatoid arthritis (RA) treated in Southern Italy. Patients’ data, activity index, and clinimetric scores were collected at baseline (T0), six...

Full description

Bibliographic Details
Main Authors:	M. Tasso, N. Bertolini, E. Mostacciuolo, S. Passavanti, J.M.E. Luppino, A. Del Puente, R. Peluso, F. Santelli, R. Scarpa, L. Costa, F. Caso
Format:	Article
Language:	English
Published:	PAGEPress Publications 2022-12-01
Series:	Reumatismo
Subjects:	Rheumatoid Arthritis JAK inhibitors Tofacitinib Baricitinib
Online Access:	https://reumatismo.org/index.php/reuma/article/view/1511

Similar Items

Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life
by: Valentine Deprez, et al.
Published: (2020-10-01)

Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis
by: Cristina Martinez-Molina, et al.
Published: (2024-02-01)

NEW APPROACHES TO PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS: TOFACITINIB
by: E. L. Nasonov
Published: (2014-06-01)

Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis
by: Irma Convertino, et al.
Published: (2023-03-01)

JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an in-vitro B cell differentiation model and in patients with rheumatoid arthritis
by: Natalie Frede, et al.
Published: (2023-01-01)

Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I)
by: E. L. Nasonov, et al.
Published: (2020-02-01)

Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study
by: Shuhei Yoshida, et al.
Published: (2023-10-01)

Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA
by: Jan Amrhein, et al.
Published: (2020-09-01)

Effects of One-Year Tofacitinib Therapy on Lipids and Adipokines in Association with Vascular Pathophysiology in Rheumatoid Arthritis
by: Monika Czókolyová, et al.
Published: (2022-10-01)

Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials
by: Gustavo Citera, et al.
Published: (2023-11-01)

Targeting of Janus Kinases Limits Pro-Inflammatory but Also Immunosuppressive Circuits in the Crosstalk between Synovial Fibroblasts and Lymphocytes
by: Nina Yao, et al.
Published: (2021-10-01)

Treatment of rheumatoid arthritis with baricitinib or upadacitinib is associated with reduced scaffold protein NEDD9 levels in CD4+ T cells
by: Viktoria Golumba‐Nagy, et al.
Published: (2023-10-01)

Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
by: Kabir Sardana, et al.
Published: (2023-01-01)

Tofacitinib
by: Nilgün Şentürk
Published: (2022-04-01)

Efficacy of tofacitinib on rheumatoid arthritis: A retrospective single-center cohort study
by: Yuhui Qi, et al.
Published: (2023-09-01)

Baricitinib for the treatment of atopic dermatitis
by: Amelia Melo, et al.
Published: (2022-07-01)

Successful Therapy of Severe and Refractory Cutaneous Sarcoidosis with Baricitinib
by: Giuseppe Russo, et al.
Published: (2024-04-01)

Characteristics and Outcomes of Patients on Tofacitinib for Alopecia Areata or Rheumatoid Arthritis: A Retrospective Cohort Study
by: Sarah Choe, et al.
Published: (2024-01-01)

Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study
by: Chan-yuan Wu, et al.
Published: (2023-09-01)

Baricitinib retention rate: ‘real-life’ data from a mono-centric cohort of patients affected by rheumatoid arthritis
by: Caterina Baldi, et al.
Published: (2023-06-01)

Problems of pain and quality of life in rheumatoid arthritis: focus on baricitinib
by: A. E. Karateev
Published: (2020-09-01)

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
by: Kevin L. Winthrop, et al.
Published: (2022-12-01)

Effect of tofacitinib therapy on angiotensin converting enzyme activity in rheumatoid arthritis
by: Dorottya Kacsándi, et al.
Published: (2023-10-01)

THE PLACE OF TOFACITINIB IN THE TREATMENT STRATEGY OF RHEUMATOID ARTHRITIS
by: V. I. Mazurov, et al.
Published: (2018-05-01)

Efficacy and safety of different Janus kinase inhibitors combined with methotrexate for the treatment of rheumatoid arthritis: a single-center randomized trial
by: Xiaoling Liao, et al.
Published: (2023-10-01)

JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results
by: Krzysztof Szalus, et al.
Published: (2020-11-01)

Baricitinib improves pulmonary fibrosis in mice with rheumatoid arthritis-associated interstitial lung disease by inhibiting the Jak2/Stat3 signaling pathway
by: Hongli Liu, et al.
Published: (2023-08-01)

Analysis of survival rate and persistence predictors of baricitinib in real-world data from a large cohort of rheumatoid arthritis patients
by: Simone Parisi, et al.
Published: (2024-01-01)

BARICITINIB: NEW PHARMACOTHERAPY OPTIONS FOR RHEUMATOID ARTHRITIS AND OTHER IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES
by: E. L. Nasonov, et al.
Published: (2020-06-01)

Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF-β and IL-6
by: Piero Ruscitti, et al.
Published: (2022-05-01)

Potential Mechanism of Fatigue Induction and Its Management by JAK Inhibitors in Inflammatory Rheumatic Diseases
by: Felis-Giemza A, et al.
Published: (2023-09-01)

Relieving severe itching caused by scabies with tofacitinib: A case report
by: Zhenze Yu, et al.
Published: (2023-11-01)

Intravenous immunoglobulin–refractory necrobiotic xanthogranuloma successfully treated with tofacitinib 2% cream
by: Neda Shahriari, MD, et al.
Published: (2023-02-01)

Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
by: Sofia Faria, et al.
Published: (2023-09-01)

Tofacitinib Blocks Entheseal Lymphocyte Activation and Modulates MSC Adipogenesis, but Does Not Directly Affect Chondro- and Osteogenesis
by: Tobias Russell, et al.
Published: (2021-12-01)

Co-Delivery of Loxoprofen and Tofacitinib by Photothermal Microneedles for Rheumatoid Arthritis Treatment
by: Yi Lu, et al.
Published: (2023-05-01)

Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy
by: Yuyang Han, et al.
Published: (2022-10-01)

Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter
by: Md Mehedi Hossain, et al.
Published: (2024-04-01)

Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
by: Dongfan Wei, et al.
Published: (2023-04-01)

The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
by: Diqin Yan, et al.
Published: (2022-08-01)